ARA-290

What Is ARA-290?

ARA-290 is a synthetic peptide modeled on the helix-B region of erythropoietin (EPO), the hormone best known for stimulating red blood cell production. Researchers had found that EPO also has separate, tissue-protective and anti-inflammatory effects, but using full EPO to access those effects raises red blood cell counts and cardiovascular risk, which limited its usefulness for that purpose specifically.

ARA-290 was engineered to selectively activate a different receptor pathway, called the innate repair receptor, which mediates EPO's tissue-protective effects without engaging the classical EPO receptor responsible for red blood cell production. This receptor was characterized in foundational research from Michael Brines and colleagues, and ARA-290 was designed specifically to exploit that separation.

What ARA-290 Is Being Researched For

• Neuropathic Pain

  A completed Phase 2 trial in patients with sarcoidosis-associated small fiber neuropathy found that 28 days of ARA-290 treatment improved neuropathic symptoms and increased corneal nerve fiber density, a direct measure of nerve regeneration.^[1]

• Chronic Pain Following Nerve Injury

  Earlier preclinical research in a rat model of nerve injury found ARA-290 produced long-lasting reductions in pain sensitivity, alongside suppression of spinal cord immune cell activity linked to chronic pain.^[2]

• Type 2 Diabetes and Metabolic Markers

  ARA-290 has also been studied in a Phase 2 trial in people with type 2 diabetes, examining effects on metabolic control alongside neuropathic symptoms, since diabetic neuropathy shares underlying mechanisms with the sarcoidosis-related nerve damage studied elsewhere.

How ARA-290 Works

• Activating the Innate Repair Receptor

  Research points to ARA-290 selectively binding a receptor complex called the innate repair receptor, formed by the EPO receptor pairing with a separate protein called the beta-common receptor (CD131). This receptor is upregulated specifically in injured and inflamed tissue, which is part of why ARA-290's effects are concentrated where tissue damage has occurred.^[1][2]

• Reducing Inflammation Without Raising Red Blood Cells

  Research points to ARA-290 suppressing pro-inflammatory signaling, including the NF-kB pathway, while specifically not activating the classical EPO receptor responsible for red blood cell production, which is the core design distinction separating it from EPO itself.

• Long-Lasting Pain Relief Through Spinal Cord Effects

  Research points to ARA-290 producing pain relief that outlasted the treatment period in animal studies, associated with reduced activation of spinal cord microglia and astrocytes, immune cells linked to the maintenance of chronic pain states.^[2]

Reconstitution and Handling

ARA-290 is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

ARA-290's defining feature is its engineered separation of erythropoietin's tissue-protective effects from its red-blood-cell-stimulating activity, allowing researchers to study EPO's anti-inflammatory and nerve-protective properties without the cardiovascular risk that comes with raising hematocrit. It has genuine Phase 2 human trial data showing measurable nerve regeneration and pain improvement, which is a meaningfully more advanced evidence base than most compounds on this site. Its further clinical development has stalled, however, following the closure of the company that held it, leaving Phase 3 data an open question.

Frequently Asked Questions

Sources and Research

1. Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19(1):334-345.
2. Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014;10:13.